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EXTRA VIEW
Disease-associated protein seeding suggests a dissociation
between misfolded protein accumulation and
neurodegeneration in prion disease
James Alibhaia, Abigail Diackb, and Jean Mansonb
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University of Edinburgh, Edinburgh, UK;
bNeurobiology Division, The Roslin Institute, University of Edinburgh, Easter Bush, UK
ABSTRACT. Chronic neurodegenerative diseases, such as prion diseases or Alzheimer’s disease, are
associated with progressive accumulation of host proteins which misfold and aggregate.
Neurodegeneration is restricted to specific neuronal populations which show clear accumulation of
misfolded proteins, whilst neighbouring neurons remain unaffected. Such data raise interesting
questions about the vulnerability of specific neuronal populations to neurodegeneration and much
research has concentrated only on the mechanisms of neurodegeneration in afflicted neuronal
populations. An alternative, undervalued and almost completely unstudied question however is how
and why neuronal populations are resilient to neurodegeneration. One potential answer is unaffected
regions do not accumulate misfolded proteins, thus mechanisms of neurodegeneration do not become
activated. In this perspectives, we discuss novel data from our laboratories which demonstrate that
misfolded proteins do accumulate in regions of the brain which do not show evidence of
neurodegeneration and further evidence that microglial responses may define the severity of
neurodegeneration.
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Nascent proteins need to be specifically
folded to gain functional activity and incorrect
protein folding can be detrimental potentially
resulting in cell death. Mechanisms maintain-
ing regular protein folding and either refold or
mark misfolded proteins for degradation are of
critical importance for maintaining a healthy
organism. This phenomenon is termed proteo-
stasis, which has been extensively reviewed
elsewhere.1-3 A number of diseases are associ-
ated with the accumulation of misfolded or
improperly degraded proteins, indicating that
when the mechanisms of regulating proteosta-
sis fail this can lead to severe manifestations of
cellular and multi-cellular degradation and
death. Over 50 human diseases have been iden-
tified to be related to protein misfolding,4
which manifest in many different tissues such
as the heart, kidney, pancreas, liver and the
brain.3-6
One of the most prevalent and increasingly
common categories of protein misfolding disor-
ders are age-related neurodegenerative diseases
such as Alzheimer’s disease.7 It is understood
that the accumulation and aggregation of aber-
rantly folded host proteins in the central nervous
system (CNS) is responsible for initiating or
inhibiting a cascade of pathways which eventu-
ally lead to neuronal degeneration and death.
However, the mechanism(s) of neurodegenera-
tion and the exact role that the disease-associ-
ated misfolded proteins play remain elusive.
The accumulation of misfolded proteins in
chronic neurodegenerative diseases suggest a
failure of proteostasic mechanisms. Indeed a
number of studies have demonstrated deficits of
proteostasis associated with neurodegenerative
diseases, such as impairments in protein degra-
dation pathways,8-11 dysregulation or reduction
of molecular chaperones12 and improper or
impaired stress response pathway activation.13,14
It has been well documented that misfolded
protein aggregates are targeted to specific neu-
ronal populations of the CNS during chronic
neurodegenerative diseases and that the distri-
bution of these aggregates appears to spread
between neuroanatomical connected regions
with neighbouring neuronal populations
remaining unaffected.15-19 These studies have
utilised relatively insensitive pathology
techniques to detect the misfolded protein
aggregates because no higher sensitive methods
have existed for the detection of the misfolded
protein isoforms within in vivo tissue. What is
detected using these methods is almost cer-
tainly the end result of a progressive cascade of
aberrant protein folding and proteostasis
impairment. An exception to this rule is found
in prion diseases, where several research
groups have independently developed ultra-
sensitive methods for the detection of mis-
folded prion protein (PrP).20-22 These methods
work by using misfolded PrP to act as a “seed”
to convert normally folded PrP to a disease-
associated isoform. Due to the dynamics of
these assays, extremely small quantities of mis-
folded protein can be used to seed the conver-
sion process – thus in any sample, one can
detect quantities of misfolded protein that can-
not be detected by other methods. As a result,
detection using these methods can identify iso-
forms of disease-associated protein which
accumulate prior to forms characterised by tra-
ditional detection methods.23 Recent advances
have also utilised this same method to detect
a-synuclein seeds, albeit to lower levels of sen-
sitivity at present.24
A recent study in our laboratory used these
sensitive methods to probe the distribution of
misfolded PrP, which act as seeds, over a time-
course in the brains of mice experimentally
infected with a prion disease.23 In this mouse
model of disease, neurons in specific brain
regions progressively degenerate and eventually
die within a predictable time-course. Impor-
tantly, there are brain regions which appear to
remain completely unaffected by disease as
assessed using a range of pathological markers
of disease. Our study compared regions of neu-
rodegeneration to those regions which appear
resilient to neurodegeneration. Our hypothesis
was that the early progenitors of misfolded PrP,
detected using the highly sensitive techniques
described above, would be processed and
degraded by cells differently between brain
regions and thus enable an in depth examination
of the molecular events leading to impaired pro-
teostasis and consequent misfolded protein
aggregation. However, we observed an accumu-
lation of misfolded PrP in all brain regions
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tested using our sensitive techniques, regardless
of whether a brain region was resilient or sus-
ceptible to neurodegeneration.23 This data dem-
onstrated that the molecular events of protein
misfolding were widespread across the brain.
Further examination during the time-course
revealed the initial time point of detection of
misfolded PrP was the same in all brain regions
tested, demonstrating that the protein misfold-
ing events spread rapidly across the brain,
rather than slowly progressing between neuro-
nal populations as previously understood.
Importantly, the accumulation across all brain
regions tested showed no relationship to the
appearance and progression of neurodegenera-
tion. Another consideration was whether the
misfolded PrP detected was present at different
quantities, and if so, whether the regions exhib-
iting higher quantities would be correlated with
neurodegeneration. We found that the levels of
misfolded PrP were approximately equal across
all brain regions tested. Taken together, this
data showed that neither the time at which the
initial seeds for protein misfolding accumulate,
nor the quantity that misfolded PrP rises to,
could define whether a brain region was suscep-
tible or resilient to neurodegeneration. This
data therefore suggests that the accumulation
of misfolded PrP, alone, is not sufficient for
neurodegeneration and thus raises important
questions about the role of misfolded proteins
within the mechanism of neurodegeneration.
One potential explanation is conformation
and types of aggregate that form between brain
regions may differ with some being proportion-
ally more toxic compared to others. A second
explanation would be the physiological and
functional differences between cells in different
brain regions, which contrast in their response
to accumulation of misfolded protein aggre-
gates. Taken individually both arguments are
convincing, yet fail to fully explain the com-
plexities of disease progression. For example,
distinct conformations or aggregates have been
extensively characterised in the literature
(reviewed25) with a number of different aggre-
gates being associated with neurodegeneration,
however it remains unclear how and why cer-
tain aggregates are able to form in vivo. At a
most basic level, protein folding is controlled
by a preference to fold to the most thermody-
namically stable state immediately, during and
after translation and post-translational modifi-
cations. In all cases of chronic neurodegenera-
tive disease associated with protein misfolding,
the disease associated protein species is a host
encoded protein which in the majority of indi-
viduals remain stable throughout life. Thus, for
a host encoded protein to result in a ‘misfolded’
isoform which then aggregates would require a
significant change in the thermodynamic state
of the local microenvironment that the protein
exists within. Therefore we argue the more rel-
evant question is what are the major physiolog-
ical differences between brain regions which
might confer resilience or susceptibility to
neurodegeneration?
In our study, for example, we used gross
anatomical dissection of four different brain
regions each containing an array of neuronal
types unique to specific microdomains of the
brain, each utilising different neurotransmit-
ters, stress responses, metal ions and have
widely varying metabolic activities, amongst
many other differences. Each of these differ-
ences could, and likely does, contribute to
determining selective vulnerability of specific
neuronal populations but is a highly complex
phenomenon and has been extensively
reviewed elsewhere.26 Recent studies, how-
ever, have demonstrated and characterised
unique features amongst other cell types of
various brain regions, such as microglia27 and
astrocytes.28 For example, microglia have
been demonstrated to exhibit significant dif-
ferences in gene expression across brain
regions of a healthy mouse brain which also
alternately change expression during ageing.
The major role for microglia in the healthy
brain is to constantly evaluate their local
microenvironment for insult and injury but
also to provide trophic support to neurons.
Due to their responsive nature, it is feasible
the distinctive microglial profiles are the
result of the underlying physiological differ-
ences between brain regions founded by the
distinct resident neuronal populations,
although this has not yet been studied. Thus,
it is plausible that the varying glial cell
responses could be major contributors to
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region-specific vulnerabilities during chronic
neurodegeneration.
In instances of disease, microglia respond
by expressing a range of genes associated
with a well characterised innate immune
response.29 Alternatively, astrocytes play an
important, yet still poorly defined role in
prion-associated immune responses. Astro-
cytes respond to disease by substantially
upregulating their intermediate filamentary
protein, GFAP, a marker for astrogliosis. It
is unclear what impact this cellular activa-
tion has in prion disease mechanisms but
there is growing evidence to suggest astro-
cytes play an important immune role during
disease by their communication with micro-
glia. For example, early studies suggest that
a co-culture of astrocytes and neurons incu-
bated with prions followed by experimental
inoculation into mice had chemotactic prop-
erties that inoculation of prions alone, with-
out co-culture, did not exhibit.30 This
suggests that astrocyte and/or neuronal sig-
nalling are responsible for microglial recruit-
ment and activation to sites of prion
infection. Other studies have indicated that
the pro-inflammatory associated cytokine,
IL-1b, appears to play an important role in
astrogliosis as mice deficient in IL-1b exhib-
ited attenuated astrogliosis.31 Another study
showed by microinjection of IL-1b or TNFa
into mice experimentally infected with prion
disease that IL-1b synthesis is more robust
but this occurred exclusively in microglia.32
This would indicate a communication
between the microglia activated by such
cytokines and astrocytes when considering
this in the context of reduced astrogliosis in
mice deficient in IL-1b.31 Furthermore, the
microinjection of IL-1b or TNFa also dem-
onstrated that astrocytes activate NFkB
which relates to the expression of chemo-
kines in response to cytokine challenge.32
Taken together, the role of the astrocyte in
mediating immune reactions appears intrinsi-
cally linked with microglial activation,
whereby microglial activation may play a
role in activating astrogliosis which in turn
produces a robust chemokine signal to attract
additional populations of microglia to the
areas of prion-associated pathology. One
may then envisage this cellular activity as a
chronic feedback loop which further propa-
gates the immune response to prion disease.
In our study we examined the cellular
responses at the transcriptional level within brain
regions which show neurodegeneration and com-
pared these to brain regions which appeared
resilient to neurodegeneration, yet both accumu-
late misfolded proteins.23 We identified major
gene expression changes in all brain regions
tested, including those that show no apparent
neurodegeneration in the presence of misfolded
protein aggregates. Upon further investigation of
the most significantly altered profiles identified a
set of genes which substantially correlated with
previously published datasets of microglial tran-
scriptomic experiments and gene ontology
descriptions corresponding to those expected of
a cell which controls the innate immune
responses within the brain. Therefore we estab-
lished that the major gene expression changes in
all brain regions occur in microglia. Upon fur-
ther analysis it was apparent that the microglial
response was different between brain regions,
with at least two distinct profiles of the micro-
glia. Activation of the innate immune response
was restricted to regions of neurodegeneration
while activation of pathways which can regulate
homeostasis was apparent in all brain regions
tested. Therefore, we determined that microglia
are the primary responsive cell in the brain dur-
ing neurodegenerative disease but more impor-
tantly the specific type of response that
microglia elicited corresponded to whether a
brain region would succumb to neurodegenera-
tion or remain apparently resilient.
Previous studies have shown changes in dis-
ease severity when manipulating the microglial
response, for example by either knockout of
specific pro- or anti-inflammatory genes,33 by
targeting specific pathways to limit microglial
proliferation34 or by microglial ablation.35
When considering this data in the context of a
diverse and complex microglial response, it can
be argued that the expression profile of micro-
glia is likely having a significant impact on the
degree of severity of neurodegeneration between
brain regions. In addition, current perspectives
of microglia in the normal brain have produced
4 J. Alibhai et al.
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compelling evidence to indicate that microglia
play an important role in regulating neuronal
homeostasis, synaptic plasticity and providing
trophic support.36 In this context this data there-
fore would suggest that the upregulation of
many genes associated with homeostasis by
microglia in brain regions showing protein mis-
folding but no neurodegeneration, but impor-
tantly in the absence of an innate immune
response, may be a neuroprotective mechanism.
Furthermore, recent studies have demonstrated
that specific activated microglial states can
induce distinct astrocyte expression profiles and
functions.28 Importantly, the differences in
induced astrocyte profile appears to have an
important role in defining toxicity28 and there-
fore further understanding the interaction
between the different microglial activation states
and their interaction with astrocytes could be
valuable to aiding our understanding of why
some brain regions appear resilient or suscepti-
ble to neurodegeneration in the presence of prion
seeding activity.
One of the major challenges for drug
development in chronic neurodegenerative
diseases is firstly what pathological feature
should be targeted in order to ameliorate
pathogenesis, secondly how to specifically
deliver therapy to areas of the central nervous
system that are undergoing neurodegeneration
and thirdly how to intervene at an early
enough stage to deliver an effective therapy.
Arguably, the most challenging answer to
these is the first point, what pathology to ther-
apeutically target. Neurodegenerative diseases
are extremely complex and exhibit a great
deal of pathologies, ranging from the protein
misfolding, lack of proteostasis, mitochon-
drial deficits, ER stress, microglial responses,
amongst many others. It is therefore unlikely
that targeting a single aspect of the pathology
will result in therapy that can either prevent
clinical onset or offer substantial benefits to
patients. Instead, a stronger approach would
be to target a combination of pathologies.
Thus we need to identify targets that would
have the best chance of modifying disease.
By their nature, microglia are responsive cells
and our data combined with other studies
indicates that the microglial response can be
actively manipulated during disease. As a
result microglia could represent the most
promising disease modifying target as they
will be the most impressionable to change.
Furthermore, if with future research efforts
we can understand the complex microglial
response and understand the driving processes
behind the activation of the homeostasis
response exhibited in brain regions that
appear resilient in our study, it is feasible that
microglia could not only be prevented from
being a contributor to the severity of neurode-
generation, but instead be re-programmed to
activate an alternate and potentially neuropro-
tective response. This may represent the first
tangible step in a therapy which can then add
new targets acting on other aspects of the
neuropathology.
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